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ORIGINAL RESEARCH • CONTRAST MEDIA
For more than 20 years, gadolinium-based contrast agents (GBCAs) have been a cornerstone of clinical MR imag-
ing (MRI) examinations (1,2). Since the initial approval of 
these agents in the 1980s, they have been considered stable 
agents with an excellent safety profile at recommended dos-
age levels (2,3).
In 2005 and 2006, researchers described a correlation 
between the repeated and cumulative administration of 
GBCAs and the development of a potentially life-threat-
ening disease, nephrogenic systemic fibrosis, in patients 
with impaired renal function (4,5). In 2013, Kanda et al 
(6) described a correlation between GBCA administra-
tion and hyperintensity on unenhanced T1-weighted MR 
images in the globus pallidus and the dentate nucleus in 
patients with a history of multiple GBCA-enhanced MRI 
examinations. Since then, a variety of clinical and animal 
studies have shown that this signal hyperintensity on 
T1-weighted images is associated with serial injections 
of linear and rarely macrocyclic GBCAs (1,7–11). Sub-
sequent histopathologic autopsy studies with inductively 
coupled plasma mass spectrometry (ICP-MS) confirmed 
brain gadolinium deposition in subjects who underwent 
GBCA-enhanced MRI examination with either a linear 
or a macrocyclic GBCA (12–14).
Safety concerns regarding the retention of gadolinium in 
the brain have consequently emerged (3,15). The U.S. Food 
and Drug Administration has recommended that health 
care professionals reassess the necessity of repetitive GBCA-
enhanced MRI examinations in established treatment pro-
tocols in order to reduce the potential for gadolinium ac-
cumulation (16). In addition, the Pharmacovigilance Risk 
Assessment Committee of the European Medicines Agency 
has recently recommended suspension or limitation of the 
marketing authorizations for four linear GBCAs (17).
The underlying mechanism of the initial pathway and 
subsequent deposition of GBCAs in the brain has not yet 
been identified. As a potential pathway for GBCA entry 
into the brain, GBCA penetration from the blood into 
the cerebrospinal fluid (CSF) was recently examined in an 
animal study in healthy rats (7). Our hypothesis was that 
GBCA penetration into the CSF also occurs in humans. 
This study was performed to corroborate our hypothesis 
and evaluate whether gadolinium can be detected in hu-
man CSF after GBCA-enhanced MRI.
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Purpose: To evaluate whether gadolinium penetrates human cerebrospinal fluid (CSF) after MR imaging (MRI) with a gadolinium-
based contrast agent (GBCA).
Materials and Methods: For this retrospective study, the authors analyzed 60 CSF samples from 57 patients (median age, 50 years; 
range, 3–92 years) who underwent one contrast material–enhanced MRI examination with gadoterate meglumine within 60 days 
of CSF extraction between January and December 2016. CSF samples from patients who underwent MRI without contrast mate-
rial administration (n = 22) or those who underwent contrast-enhanced MRI at least 1 year before extraction (n = 2) were analyzed 
and used as control samples. CSF measurements were performed with inductively coupled plasma mass spectrometry by monitor-
ing the gadolinium 158 isotope. Statistical analyses were performed by using a preliminary Kruskal-Wallis test.
Results: Higher CSF gadolinium concentrations were detected within the first 8 hours after GBCA administration (mean concen-
tration, 1152 ng/mL 6 734.6). Concentrations were lower between 8 and 48 hours (872 ng/mL 6 586). After 48 hours, gadolini-
um was almost completely cleared from CSF (121 ng/mL 6 296.3). All but two samples from the 24 control patients (median age, 
60.5 years; range, 19–79 years) were negative for the presence of gadolinium. Those samples were from patients who had undergone 
GBCA-enhanced MRI examination more than a year before CSF extraction (0.1 and 0.2 ng/mL after 1 and 3 years, respectively). 
The concentrations in patients with chronic renal insufficiency (n = 3), cerebral toxoplasmosis (n = 1), and liver cirrhosis (n = 1) 
were higher than the mean concentrations.
Conclusion: Gadoterate meglumine can be detected in human CSF after intravenous administration.
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Materials and Methods
Study Design
Our institution received an unrestricted research grant from 
Guerbet Imaging Switzerland. The company was not involved 
in our study design, data collection, data analysis, interpreta-
tion, or manuscript preparation. In our retrospective study, we 
performed a comprehensive review of our institute’s health care 
databases, digital medical files, and patient histories to obtain a 
complete list of all patients who had undergone lumbar punc-
ture and previous GBCA-enhanced MR image acquisition in 
2016. Data analysis was performed by two radiologists (R.A.K., 
with 25 years of experience in clinical radiology, and F.B., with 
4 years of experience in clinical and forensic radiology). The 
focus of our study was the macrocyclic GBCA gadoterate 
meglumine because of the high prevalence of its use in our 
institution and in Switzerland. Patients from our outpatient 
department who had undergone contrast material–enhanced 
MRI examinations with a different GBCA were rarely seen in 
our emergency ward and did not undergo lumbar puncture. 
Our study was approved by the local ethics committee, which 
authorized the use of CSF samples from 2016 (project identi-
fication: 2016-02168). No power calculations were performed 
because the aim of our study was to prove a hypothesis and 
basic data for assumption of the effect size were not available.
Participants
Included were all patients in our institution who underwent 
lumbar puncture between January and December 2016 and 
one previous MRI examination with the macrocyclic GBCA 
gadoterate meglumine (at a dose of 0.1 mmol per kilogram body 
weight) up to 60 days before CSF extraction. For each patient, 
we performed a comprehensive review of internal digital medical 
files to obtain a complete GBCA history and a complete patient 
questionnaire form from previous MRI examinations. Patients 
were excluded if there was inconclusive history and unknown 
time of GBCA application, if they had undergone multiple ad-
ministrations of gadoterate meglumine, if there were insufficient 
laboratory results at the time of MR imaging, or if the diagnosis 
was unclear at the time of patient recruitment. Samples with less 
than 4 mL of CSF were also excluded to ensure that enough CSF 
remained for potential clinical repeat analysis.
Exposures and Outcomes
In 2016, 292 lumbar punctures were performed at our insti-
tution to exclude any central nervous system disorder; 98 pa-
tients had undergone contrast-enhanced MRI with gadoter-
ate meglumine at a dose of 0.1 mmol per kilogram body 
weight up to 60 days before lumbar puncture. Of these, 38 
CSF samples did not fulfill the inclusion criteria and were ex-
cluded. The majority of these samples were excluded because 
of insufficient sample size (n = 27) or multiple administra-
tions of gadoterate meglumine (n = 8) (Fig 1). A total of 60 
CSF samples from 57 patients were eventually analyzed in 
our study. Forty-seven of the 57 participants underwent lum-
bar puncture because of neurologic disorders. The remaining 
10 participants had psychiatric (n = 2), neoplastic (n = 5), or 
other (n = 3) disorders. For each patient, laboratory results 
(serum creatinine level, estimated glomerular filtration rate, 
C-reactive protein level, and aspartate aminotransferase level) 
at the time of MRI examination were collected from our ex-
tended health care network. In total, 28 of the CSF samples 
showed an elevated total CSF protein count (.0.45 g/L; 
range, 0.48–2.2 g/L); the remaining CSF samples showed 
no abnormalities. The CSF samples were divided into three 
subgroups depending on the time between GBCA adminis-
tration and CSF extraction, as follows: subgroup 1 (n = 31), 
0–8 hours; subgroup 2 (n = 13), 8–48 hours; and subgroup 3 
(n = 16), 2–60 days.
Twenty-four patients were enrolled in a control group. Of 
these, all but one patient had neurologic disorders, including cere-
brovascular insult, paresthesia, Guillain-Barré syndrome, syncope, 
peripheral facial paralysis, and meningitis. The other patient was 
diagnosed with B-cell lymphoma. Of the 24 patients in the con-
trol group, 22 had not undergone MRI or had undergone unen-
hanced MRI and two had undergone GBCA-enhanced MRI at 
least 1 year before CSF extraction (1 and 3 years, respectively), as 
recorded in our medical files. All other inclusion criteria were the 
same as for the GBCA group. All patients in the contrast and con-
trol groups lived within the canton of Aargau, Switzerland, and 
received the majority of their health care at our medical center 
or within our extended health care network, which permitted ac-
cess to their previous radiologic examinations. Most CSF samples 
in the control group (n = 17) showed no abnormalities. The to-
tal CSF protein count in the remaining seven CSF samples was 
greater than 0.45 g/L (range, 0.52–1.04 g/L).
Determination of CSF Total Gadolinium 
Concentration
Sample preparation for ICP-MS.—All CSF samples were ano-
nymized. The laboratory staff was blinded to group allocation and 
had no access to the study data. Sample analysis was performed by 
an experienced forensic toxicologist (M.P., with 7 years of experi-
ence in forensic pharmacology and toxicology). A 0.3-mL aliquot 
Abbreviations
CSF = cerebrospinal fluid, GBCA = gadolinium-based contrast agent, 
ICP-MS = inductively coupled plasma mass spectrometry, IQR = in-
terquartile range
Summary
After contrast-enhanced MRI examination, gadoterate meglumine can 
easily penetrate into cerebrospinal fluid and is cleared from cerebrospi-
nal fluid over time.
Implications for Patient Care
 n Gadoterate meglumine, a macrocyclic gadolinium-based contrast 
agent, can penetrate into human cerebrospinal fluid (CSF) after 
intravenous administration.
 n CSF gadolinium concentration increases within the first 8 hours 
after intravenous contrast agent administration and then decreases 
between 8 and 48 hours.
 n Gadoterate meglumine was almost completely cleared from the 
CSF after 48 hours.
Berger et al
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Results
Determination of CSF Total Gadolinium 
Concentrations
Reliable quantification of gadolinium in CSF samples was eas-
ily achieved with ICP-MS. Simple dilution of the CSF samples 
with ultrapure water was sufficient for achievement of inter-
ference-free (tested with blank samples) measurements. Lin-
earity (given as R2) was always better than 0.9995. All stable 
gadolinium isotopes (152Gd, 154Gd, 155Gd, 156Gd, 157Gd, 158Gd, 
and 160Gd) were measured, and the 158Gd isotope was used for 
quantification. In positive cases, measurement of the other 
gadolinium isotopes led to almost identical results (,10% dif-
ference). The external controls, measured before and after each 
series, did not show any drift in results.
Patient Populations
A total of 60 CSF samples from 57 patients (29 female and 28 
male patients) were analyzed. The median age of patients in the 
contrast group was 50 years (range, 3–92 years). The contrast 
group was divided into subgroups on the basis of the interval 
between GBCA administration and CSF extraction, as follows: 
subgroup 1, 0–8 hours; subgroup 2, 8–48 hours; and subgroup 
3, 2–60 days. The median age of the patients in subgroup 3 at the 
time of MRI examination (68 years [IQR, 43.5–78.5 years]) was 
higher than that in subgroup 1 (48 years [IQR, 28–59 years]; P 
= .04), subgroup 2 (48 years [IQR, 36–73 years]; P = .48), and 
the control group (60.5 years [IQR, 50.5–67.8 years]; P = .56). 
In the contrast group, three male patients had undergone two 
lumbar punctures after GBCA-enhanced MRI examination: at 
2.3 hours and 5.4 days after examination, at 7.3 and 21.5 hours 
after examination, and at 5.0 and 11.3 days after examination, 
respectively.
Gadolinium was detected in all CSF samples from the con-
trast group, with an overall mean concentration (6standard 
of the sample was diluted with ultrapure water to 
3.0 mL. All calibration standard solutions were 
prepared from 1 mg/mL single-element standard 
solutions (Merck, Darmstadt, Germany) by means 
of dilution with ultrapure water.
Performance of ICP-MS.—An Analytik Jena 
PlasmaQuant MS instrument (Analytik Jena, 
Jena, Germany) in the highest stage of completion 
(Elite version), equipped with a type 142 Varian 
cooler and a Varian SPS 3 Autosampler (Varian, 
Darmstadt, Germany), was used for quantification 
of gadolinium isotopes. with the following mea-
surement parameters: analysis type: quantitative; 
acquisition mode: steady state; scan mode: peak 
hopping; spacing, coarse, points per peak: I; scans 
per replicate: 20; replicates per sample: 3; plasma: 
plasma flow, 7.50 L/min; auxiliary flow: 1.40 L/
min; sheath gas flow: 0.00 L/min; nebulizer flow: 
0.99 L/min; sampling depth: 5.00 mm; ion op-
tics (volt): skimmer bias, 0.00; first extraction 
lens: 270.00; second extraction lens: 2306.00; third extrac-
tion lens: 2370.00; left mirror lens: 60.00; right mirror lens: 
31.00; bottom mirror lens: 37.00; corner lens: 2318.00; en-
trance lens: 3.00; fringe bias: 24.50; entrance plate: 296.00; 
collision reaction interface: skimmer cone, helium; skimmer 
gas flow: 80 mL/min; sampling: aerosol generation, nebu-
lizer; source: autosampler; fast pump during sample delay and 
rinse: on; rinse time: 40 seconds; spray chamber temperature: 
3.00°C; sample uptake delay: 60 seconds; scanning time: 181 
minutes; and replicate time: 3.62 seconds. Gadolinium iso-
topes 152, 154, 155, 156, 157, 158, and 160 were measured, 
and gadolinium 158 (158Gd) was used for quantification.
All chemicals and materials were checked for interfer-
ences. Calibration was performed for every series by using 
standard solutions of 0.01, 0.1, 1, and 10 µg gadolinium 
per liter and a blank sample. The aforementioned calibration 
range samples were diluted and measured again to fit to the 
calibration range. Dotarem production samples (Guerbet, 
Zurich, Switzerland) containing 0.5 mmol of gadolinium per 
milliliter were used as external controls and analyzed before 
and after a measurement series.
Statistical Analysis
Statistical analyses were performed by two readers (F.B. and 
T.K., with 29 years of experience in clinical and forensic phar-
macology and toxicology). For statistical analysis of the data 
(Grubbs outlier test, Kruskal-Wallis test), software was used 
(GraphPad Prism 6 [GraphPad Software, La Jolla, Calif ] and 
R, version 3.1.0 [R Foundation for Statistical Computing, Vi-
enna, Austria]). Continuous variables are presented as medi-
ans, interquartile ranges (IQRs), and ranges, owing to nonnor-
mal data distributions, unless otherwise noted. Comparison of 
all four groups (three subgroups and the control group) was 
performed by using a preliminary Kruskal-Wallis test with post 
hoc correction at a = .05. Significance was assigned to differ-
ences with P  .05.
Figure 1: Flowchart shows formation of study group with exclusion criteria. CSF = 
cerebrospinal fluid, GBCA = gadolinium-based contrast agent, ICP-MS = inductively 
coupled plasma mass spectrometry.
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In subgroup 3 (n = 16 samples), the mean CSF gadolinium 
concentration was 121 ng/mL 6 296.3 (range, 0.1–1118.8 ng/
mL). The median interval between GBCA administration and 
CSF extraction was 5.7 days (IQR, 3.2–11.8 days). The main 
diagnoses in subgroup 3 were neurologic disorders (n = 12), neo-
plastic disorders (n = 3), and chronic renal failure (n = 1) (Table 3). 
The gadolinium concentration 3 days after GBCA administration 
was higher in a patient with chronic renal failure (531.7 ng/mL) 
compared to the two patients whose samples were obtained 3.2 
days after MRI examination (44.0 and 19.0 ng/mL, respectively).
A 21-year-old male patient with viral meningoencephalitis un-
derwent lumbar punctures at 2.3 hours and 5.4 days after GBCA 
administration and showed a clear decrease in gadolinium con-
centration, from 522 to 1.9 ng/mL, during the 5-day period. The 
other two patients with two lumbar punctures showed a similar 
decrease from 1885 to 1508.2 ng/mL (at 7.3 and 21.5 hours) and 
from 43.9 to 1.9 ng/mL (at 5.0 and 11.3 days), respectively.
In the control group, all samples were negative for the pres-
ence of gadolinium except the two CSF samples from the pa-
tients who had undergone a GBCA-enhanced MRI examina-
tion more than a year before CSF extraction. These samples had 
gadolinium concentrations of 0.1 and 0.2 ng/mL in CSF after 1 
and 3 years, respectively.
Discussion
The results of our study confirm the presence of gadolinium in 
human CSF after MRI with the macrocyclic GBCA gadoterate 
meglumine and demonstrate a decrease in CSF gadolinium con-
centration over time. Higher CSF gadolinium concentrations 
were detected within the first 8 hours after GBCA administra-
tion (mean concentration, 1152 ng/mL 6 735), whereas the 
gadolinium concentrations were lower between 8 and 48 hours 
(mean concentration, 872 ng/mL 6 586) and after 48 hours 
(mean concentration, 121 ng/mL 6 296).
Previous studies showed that a higher signal intensity can 
be detected with MRI in various cranial fluid spaces after the 
administration of a GBCA (18–21). Naganawa et al (20,21), 
for instance, detected contrast enhancement in CSF and perivas-
cular spaces with heavily T2-weighted three-dimensional fluid-
attenuated inversion-recovery MRI after intravenous GBCA 
administration, a finding that suggests GBCA penetration into 
cranial fluids. We confirmed these early findings by using an ab-
solute gadolinium detection method (ICP-MS) rather than sim-
ply inferring the presence of gadolinium by means of elevated 
signal intensities.
In their study in healthy rats, Jost et al (7) demonstrated 
that both linear and macrocyclic GBCAs are almost completely 
cleared from CSF within 24 hours. Our results are in accordance 
with the findings of this preclinical study and demonstrated an 
almost complete clearance of gadoterate meglumine from CSF 
48 hours after administration. In the contrast groups, the elimi-
nation of gadoterate meglumine from CSF is further shown in 
the decrease in gadolinium concentration over time in the CSF 
samples of three male patients with two subsequent lumbar 
punctures.
Gadolinium could be detected even in subjects with a presum-
ably intact blood-brain barrier. This suggests GBCA penetration 
deviation) of 816.1 ng/mL 6 746.6 (range, 0.1–3481.9 ng/
mL). A comparison of median values and ranges in the three 
subgroups can be seen in Figure 2. There was no difference in 
gadolinium concentration between female and male patients (P 
= .91). Furthermore, the independent variables of liver function 
and inflammatory parameters did not influence the CSF gado-
linium concentration (P = .77 and P = .39, respectively).
In subgroup 1 (n = 31 samples), CSF gadolinium concentration 
ranged from 167.9 to 3481.9 ng/mL, with a mean concentration 
of 1151.5 ng/mL 6 734.6. The median interval between GBCA 
administration and CSF extraction was 4.6 hours (IQR, 3.3–5.3). 
As shown in Table 1, the main diagnoses in this group were as 
follows: neurologic disorders (n = 29), psychiatric diseases (n = 
1), and others (n = 1). Statistical analysis with the Grubbs test 
identified the highest gadolinium concentration of 3481.9 ng/
mL in a female patient with newly diagnosed human immu-
nodeficiency virus infection with cerebral toxoplasmosis as an 
outlier. Most patients in subgroup 1 had an estimated glomeru-
lar filtration rate greater than 60 mL/min/1.73 m2. Only two 
patients had a lower estimated glomerular filtration rate (45 and 
20 mL/min/1.73 m2) and CSF gadolinium concentrations that 
were higher than the mean concentration (1945 and 2256.7 ng/
mL). In subgroup 1, the only patient with liver cirrhosis also had 
a gadolinium concentration that was among the highest (2211.5 
ng/mL 6.3 hours after GBCA administration).
Concentrations in subgroup 2 (n = 13 samples) ranged from 
17.8 to 2140.7 ng/mL, with a mean concentration of 871.7 ng/
mL 6 586.1. The median interval between GBCA-enhanced 
MRI examination and lumbar puncture was 23.4 hours (IQR, 
8.9–26.5). The main diagnoses were neurologic disorders (n = 
9), psychiatric diseases (n = 1), neoplastic disorders (n = 2), and 
other diagnosis (n = 1) (Table 2). Compared with the other sub-
groups and the control group, subgroup 2 showed a higher me-
dian C-reactive protein level (8.0 mg/L [IQR, 2.0–17.0 mg/L]) 
and aspartate aminotransferase level (31.0 U/L [IQR, 20.0–47.0 
U/L]), although the differences were not statistically significant 
(P = .64 and P = .84, respectively).
Figure 2: Box plot shows gadolinium levels measured in cerebrospinal 
fluid (CSF) with inductively coupled plasma mass spectrometry and 
decrease of CSF gadolinium concentration over time.
Berger et al
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Table 1: Characteristics of Patients in Subgroup 1
Age (y)/Sex Major Diagnosis
eGFR (mL/ 
min/1.73 m2)
CRP Level  
(mg/L)
AST Level  
(U/L)
Interval between  
GBCA Administration  
and Lumbar Puncture (h)
Gd CSF  
Concentration 
(ng/mL)
50/F Tension headache .60 1 23 4 974.4
73/M Erysipelas of the foot .60 10 39 5.5 1447.1
35/M Paresthesia .60 1 25 2.6 1159.8
77/F Generalized epileptic seizure 45 48 53 5.2 1945.0
58/M Nonconvulsive epileptic seizure .60 70 14 3.6 1272.3
78/M Peripheral facial paralysis .60 1 40 3.3 953.9
74/F Hemichorea-hemiballismus .60 3 32 5.4 838.6
54/M Acute polyneuropathy .60 2 21 6.1 1962.1
25/F Generalized epileptic seizure .60 2 23 5.1 1001.6
19/M Acute psychosis .60 1 61 2.2 210.4
20/F Sepsis .60 18 25 3.6 167.9
49/F Clinically isolated syndrome .60 10 31 4.8 1084.1
33/M Clinically isolated syndrome .60 2 24 5.8 1700.4
33/M Viral meningoencephalitis .60 17 28 5.2 1251.4
51/F Migraine .60 1 81 3.3 649.3
54/F Flu .60 117 13 5.2 967.8
28/F Steroid-induced encephalopathy .60 11 27 3.4 388.0
43/M Vertigo .60 1 25 5.1 922.7
3/F Streptococcal infection .60 1 13 1.1 171.3
21/M Viral meningoencephalitis .60 6 18 2.3 522.0
60/F Generalized epileptic seizure,  
 chronic kidney failure
20 7 29 5.6 2256.7
28/F Intracranial toxoplasmosis, human  
 immunodeficiency virus infection
.60 1 16 3.2 3481.9
73/M Cerebrovascular insult .60 1 15 4.9 1746.0
26/M Viral meningoencephalitis .60 1 26 1.4 1052.2
92/M Focal epileptic seizures .60 25 27 7.3 1885.0
30/F Tension-type headache .60 1 32 5.9 480.4
48/M Migraine .60 1 24 4.6 441.3
31/F Nocturnal paresthesia .60 1 26 4.3 1062.2
60/F Liver cirrhosis .60 2 21 6.3 2211.5
4/F Flu .60 53 38 3.4 433.8
52/M Chronic Lyme disease .60 1 124 2.7 1054.3
Note.—Subgroup 1 had an interval of 0–8 hours between gadolinium-based contrast agent (GBCA)–enhanced MR imaging and cerebro-
spinal fluid (CSF) extraction. AST = aspartate aminotransferase (normal laboratory range for assay, 10–35 U/L), CRP = C-reactive protein 
(normal laboratory range for assay, 0.1–5 mg/L), eGFR = estimated glomerular filtration rate (normal laboratory range for assay, .60 mL/
min/1.73 m2), Gd CSF = gadolinium concentration in CSF measured with inductively coupled plasma mass spectrometry.
into CSF regardless of blood-brain barrier permeability. This is 
in accordance with a recent observation by McDonald et al (22) 
that gadolinium deposition in neural tissue occurs even in the 
absence of intracranial abnormalities that affect the blood-brain 
barrier. Future studies should focus on the influence of cranial 
lesions and blood-brain barrier disruptions on CSF gadolinium 
concentrations.
In our study subgroups, CSF levels of gadolinium in pa-
tients with chronic renal insufficiency tended to be among 
the highest (2257, 2140, and 532 ng/mL after 5.5 hours, 
25.5 hours, and 3 days after MRI, respectively), indicating 
a prolonged GBCA elimination from CSF. Furthermore, the 
outlier test revealed one case of newly diagnosed human 
immunodeficiency virus infection and central nervous system 
toxoplasmosis with significantly higher CSF gadolinium 
concentrations (3482 ng/mL 3.2 hours after MRI), a finding 
that suggests that the blood-CSF barrier is more permeable 
in patients with acute cerebral infections. Both observations 
must be verified in future studies focusing on the influence of 
renal insufficiency and cerebral infections on GBCA penetration 
and elimination.
In the control group, two CSF samples were taken from pa-
tients who had undergone enhanced MRI examination 1 and 3 
years prior to lumbar puncture, respectively. In those samples, 
traces of gadolinium could still be detected, whereas all other 
control samples were negative. It is unclear whether these find-
ings indicate an actual long-term intracranial GBCA deposi-
tion. If GBCAs were retained in CSF or in the brain, it can be 
Gadolinium Distribution in Cerebrospinal Fluid 
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entry of GBCAs into the brain. More recently, the glymphatic 
system has been discussed as a potential pathway for GBCA en-
try into the brain (23). The glymphatic system is a paravascular 
pathway for CSF and interstitial fluid exchange in the brain and 
might play a role in residual gadolinium deposition (23,24).
Our study had some limitations, including the assessment of 
only one GBCA. Further work must be performed to investigate 
assumed that they circulate among blood, CSF, brain, and other 
body tissues in constant equilibrium. Therefore, it can be argued 
that the gadolinium concentration detected in CSF by means of 
ICP-MS probably represents the GBCA remaining in all body 
tissues.
The mechanism of GBCA accumulation in the brain is still 
unknown. Jost et al (7) discussed the involvement of CSF in the 
Table 2: Characteristics of Patients in Subgroup 2
Age (y)/Sex Major Diagnosis
eGFR (mL/min/ 
1.73 m2)
CRP Level 
(mg/L)
AST Level 
(U/L)
Interval between GBCA  
Administration and  
Lumbar Puncture (h)
Gd CSF  
Concentration 
(ng/mL)
36/F Paresthesia .60 1 25 8.5 967.0
31/F Migraine .60 16 84 7.7 1073.0
51/M Generalized epileptic seizures .60 1 16 8.9 1098.2
51/M Cerebrovascular insult .60 1 37 8.9 1098.0
26/F Migraine .60 34 20 19.65 1081.1
92/M Focal epileptic seizure .60 25 124 21.5 1508.2
46/F Schizophrenia .60 3 38 23.4 184.7
85/M Chronic renal failure 51 17 91 25.4 2140.7
73/M B-cell lymphoma 50 2 31 26 869.5
74/F Cerebrovascular insult .60 74 47 26.5 722.3
47/F Paresthesia .60 13 14 27.8 267.2
61/F Paraneoplastic syndrome .60 1 21 44.4 304.2
28/F Clinically isolated syndrome .60 8 20 45.1 17.8
Note.—Patients in subgroup 2 underwent lumbar puncture 8–48 hours after gadolinium-based contrast agent (GBCA)–enhanced MR 
imaging. AST = aspartate aminotransferase (normal laboratory range for assay, 10–35 U/L), CRP = C-reactive protein (normal laboratory 
range for assay, 0.1–5 mg/L), eGFR = estimated glomerular filtration rate (normal laboratory range for assay, .60 mL/min/1.73 m2), Gd 
CSF = gadolinium concentration in CSF measured with inductively coupled plasma mass spectrometry.
Table 3: Characteristics of Patients in Subgroup 3 
Age (y)/Sex Major Diagnosis
eGFR (mL/min/ 
1.73 m2)
CRP Level 
(mg/L)
AST Level 
(U/L)
Interval between GBCA  
Administration and  
Lumbar Puncture (d)
Gd CSF  
Concentration 
(ng/mL)
75/F Cerebral metastases .60 4 110 2.0 1118.8
21/F Migraine .60 1 20 2.8 15.0
36/M Hypoxic encephalopathy .60 2 35 3.0 44.0
86/F Chronic renal failure 42 4 19 3.2 531.7
52/F Syncope .60 2 39 3.2 19.0
41/M Acute motor axonal neuropathy .60 2 25 4.2 21.2
77/M Viral meningoencephalitis .60 17 18 5.0 43.9
21/M Viral meningoencephalitis .60 6 13 5.4 1.9
60/M Vasculitis 58 3 25 6.0 16.6
80/M Normal pressure hydrocephalus .60 3 26 6.0 106.0
84/M Viral meningoencephalitis .60 6 34 7.0 11.1
77/M Viral meningoencephalitis .60 17 18 11.3 4.8
46/M Viral meningoencephalitis .60 22 34 13.1 0.3
70/F Cerebral metastases .60 1 23 50.1 0.1
68/M B-cell lymphoma .60 4 40 27.0 0.3
83/M Unclear ataxia .60 1 29 17.1 1.8
Note.—Patients in subgroup 3 underwent lumbar puncture 2–60 days after gadolinium-based contrast agent (GBCA)–enhanced MR 
imaging. AST = aspartate aminotransferase (normal laboratory range for assay, 10–35 U/L), CRP = C-reactive protein (normal laboratory 
range for assay, 0.1–5 mg/L), eGFR = estimated glomerular filtration rate (normal laboratory range for assay, .60 mL/min/1.73 m2), Gd 
CSF = gadolinium concentration in CSF measured with inductively coupled plasma mass spectrometry.
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the kinetics of gadolinium in CSF across various approved GBCAs. 
Because only internal medical databases and patient question-
naire forms were screened to obtain each patient’s MRI history, 
it is possible that previous external MRI examinations may have 
influenced CSF gadolinium concentrations. Owing to the lim-
ited number of subjects, we could not evaluate the relationship 
of gadolinium concentrations between patients with and pa-
tients without brain lesions. There was a high exclusion rate of 
38 samples; most of these (n = 27) were excluded because of the 
limited amount of CSF available in the sample.
In conclusion, our findings substantiate those of recent stud-
ies indicating that the macrocyclic GBCA gadoterate meglumine 
easily penetrates into CSF regardless of renal function and in pa-
tients with a presumably intact blood-brain barrier. More impor-
tant, our findings suggest that this GBCA is almost completely 
eliminated 48 hours after intravenous administration. Although 
we examined the CSF penetration of only one type of GBCA, 
our findings strongly argue for future research to assess the phar-
macokinetics and penetration into CSF of other GBCAs in con-
junction with central nervous system lesions.
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